A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
about
Chemotherapy and chemoprevention by thiazolidinedionesCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasPhase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.Advances in the targeted therapy of liposarcoma.Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.Retroperitoneal liposarcoma: current insights in diagnosis and treatmentClinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma.Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial resultsA new dawn for the use of thiazolidinediones in cancer therapy.Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.Antihyperglycaemic therapies and cancer risk.PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).Adiponectin and its receptor signaling: an anti-cancer therapeutic target and its implications for anti-tumor immunity.Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.Pharmacological therapies for Liposarcoma.Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transportClinical and Molecular Spectrum of Liposarcoma.The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression.
P2860
Q27011352-2C139670-AA62-4ED9-A295-2207A28BB1ABQ28076210-E28CEFC8-E945-4A05-96B9-B9EE1667330DQ33710548-3634CC46-8B20-4A5B-AF5B-C53B1EA33EA3Q34952133-91F6C832-986C-4D32-BABA-CB0B3730BC4FQ35051779-1342F95A-2FAF-4CCE-94D8-CDDE3A4FBA9DQ35066363-65036D97-F122-4959-A8E5-2679FEFBDA5FQ36073121-FB4DEB14-AA5C-4E19-9F64-9F8C2956061CQ36885846-D7B268FE-A6FA-4F1E-8FB7-2461B996874CQ36888347-16388C3E-07A5-4DA1-8EF0-E42CA48DA9C7Q37656960-C6888352-D9C7-41CB-8686-19C6BECA52E6Q38102596-29B4AF0A-9EC8-4A61-9FE3-A5C2F348D68CQ38161734-70E9D83D-0CC7-43A9-A094-1895124B0D97Q38193545-5C4096EB-8DE1-4DBA-A396-02F209BE3C8CQ38197031-8AA5FEFB-0077-4CB8-A545-993235C9F564Q38250719-748A74B0-7ACA-47D4-88B6-C9BF517CA9AAQ38270503-656731B9-3ACC-44A7-9C2E-78634B7D63BDQ38465754-4840749F-6EA5-4CD8-9985-B7CE400CFAECQ38744037-3665BDE6-53C0-4281-B928-6C2E259EE4A9Q38991731-1C198454-1757-433D-9586-3300EDB32FA6Q41975402-3FB6C66A-7D8F-49CA-95DE-038A8BB46BF4Q47315579-B03F82EB-E2AC-4EE2-8B4D-056F0BABD160Q48209593-C89133B9-7EBA-48F9-A7DE-2671AF8F70D3Q52638921-6D1C9518-C16A-4419-8F02-04C58DC83AFCQ53089247-7410DE73-1AD0-4D65-AA26-845B02BEF774
P2860
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@ast
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@en
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@nl
type
label
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@ast
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@en
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@nl
prefLabel
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@ast
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@en
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@nl
P2093
P2860
P356
P1433
P1476
A phase 1 study of efatutazone ...... ts with advanced malignancies.
@en
P2093
Abdel-Baset Halim
Andrew J Wagner
Catherine Copigneaux
George D Demetri
Hamim Zahir
Hirut Daniel
Ion Cotarla
Jimmy J Hwang
John F Deeken
P2860
P304
P356
10.1002/CNCR.27526
P407
P577
2012-05-08T00:00:00Z